- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 235/14 - Radicals substituted by nitrogen atoms
Patent holdings for IPC class C07D 235/14
Total number of patents in this class: 286
10-year publication summary
|
16
|
15
|
16
|
21
|
15
|
13
|
13
|
15
|
11
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Abbvie Inc. | 1844 |
6 |
| Actelion Pharmaceuticals Ltd | 511 |
6 |
| LG Chem, Ltd. | 17778 |
5 |
| The General Hospital Corporation | 4810 |
5 |
| X4 Pharmaceuticals, Inc. | 93 |
5 |
| VALO Health, Inc. | 184 |
5 |
| Kyoto University | 2883 |
4 |
| Nippon Shinyaku Co., Ltd. | 324 |
4 |
| Cavion, Inc. | 22 |
4 |
| Calico Life Sciences LLC | 104 |
4 |
| The Regents of the University of California | 20473 |
3 |
| AstraZeneca AB | 2823 |
3 |
| Janssen Pharmaceutica N.V. | 3287 |
3 |
| Allergan, Inc. | 2253 |
3 |
| Centre National de La Recherche Scientifique | 10841 |
3 |
| Sumitomo Chemical Company, Limited | 9057 |
3 |
| The Board of Trustees of the University of Illinois | 2742 |
3 |
| Takeda Pharmaceutical Company Limited | 2728 |
3 |
| Antabio SAS | 23 |
3 |
| Concert Pharmaceuticals, Inc. | 246 |
3 |
| Other owners | 208 |